Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic s… Read more
Steminent Biotherapeutics Inc. (7729) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.245x
Based on the latest financial reports, Steminent Biotherapeutics Inc. (7729) has a cash flow conversion efficiency ratio of -0.245x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-68.52 Million) by net assets (NT$279.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Steminent Biotherapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Steminent Biotherapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Steminent Biotherapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Steminent Biotherapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EP3
STU:EP3
|
N/A |
|
Irsa Wnt
BA:IRS2W
|
N/A |
|
FLRY3F
SA:FLRY3F
|
N/A |
|
Scherzer & Co. AG
F:PZS
|
N/A |
|
EDINBURGH WORLDW. LS-01
F:2TI
|
N/A |
|
216400
KO:216400
|
N/A |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
0.022x |
|
SCG Construction JSC
VN:SCG
|
N/A |
Annual Cash Flow Conversion Efficiency for Steminent Biotherapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Steminent Biotherapeutics Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$354.70 Million | NT$-139.41 Million | -0.393x | -68.78% |
| 2023-12-31 | NT$492.99 Million | NT$-114.81 Million | -0.233x | +44.96% |
| 2022-12-31 | NT$163.54 Million | NT$-69.20 Million | -0.423x | -87.55% |
| 2021-12-31 | NT$244.27 Million | NT$-55.11 Million | -0.226x | -109.31% |
| 2020-12-31 | NT$-12.98 Million | NT$-31.47 Million | 2.423x | -- |